>
Switch to:

Allergy Therapeutics Owner Earnings per Share (TTM)

: 0.01 (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Allergy Therapeutics's Owner Earnings per Share (TTM) ended in Jun. 2021 was $0.01. It's Price-to-Owner-Earnings ratio for today is 51.


The historical rank and industry rank for Allergy Therapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:

OTCPK:AGYTF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.04   Med: 58.75   Max: 332.5
Current: 35.5

8.04
332.5

During the past 13 years, the highest Price-to-Owner-Earnings ratio of Allergy Therapeutics was 332.50. The lowest was 8.04. And the median was 58.75.


OTCPK:AGYTF's Price-to-Owner-Earnings is ranked lower than
61% of the 469 Companies
in the Drug Manufacturers industry.

( Industry Median: 26.37 vs. OTCPK:AGYTF: 35.50 )

Allergy Therapeutics's Earnings per Share (Diluted) for the six months ended in Jun. 2021 was $-0.03. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $0.00. It's PE Ratio ratio for today is 255.00.

Allergy Therapeutics's EPS without NRI for the six months ended in Jun. 2021 was $-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2021 was $0.00. It's PE Ratio without NRI ratio for today is 255.00.


Allergy Therapeutics Owner Earnings per Share (TTM) Historical Data

The historical data trend for Allergy Therapeutics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Owner Earnings per Share (TTM)
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 - 0.02 0.01

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Owner Earnings per Share (TTM) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.02 - 0.01

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Owner Earnings per Share (TTM), along with its competitors' market caps and Owner Earnings per Share (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Owner Earnings per Share (TTM) Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Owner Earnings per Share (TTM) distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Owner Earnings per Share (TTM) falls into.



Allergy Therapeutics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Allergy Therapeutics's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 4.0
Depreciation, Depletion and Amortization 5.8
Change In Deferred Tax 0.0
5Y Average of Maintenance Capital Expenditure 2.2
Change In Working Capital 2.2
Shares Outstanding (Diluted Average) 676.7

1. Start with "Net Income" from income statement. Allergy Therapeutics's Net Income for the trailing twelve months (TTM) ended in Jun. 2021 was $4.0 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Allergy Therapeutics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2021 was $5.8 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Allergy Therapeutics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2021 was $0.0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $2.2 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Allergy Therapeutics's 5-Year Average Maintenance Capital Expenditure = $2.2 Mil

5. "Change In Working Capital" is from cashflow statement. Allergy Therapeutics's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2021 was $2.2 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Allergy Therapeutics's Shares Outstanding (Diluted Average) for the months ended in Jun. 2021 was 676.658 Mil.

Allergy Therapeutics's Onwer Earnings Per Share for Jun. 2021 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 4.0476858345021 +5.7952314165498+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-2.1954535764376+2.2047685834502)/676.658
=0.01

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.51/0.01
=51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Allergy Therapeutics Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)